Cardiac Arrest and Sudden Cardiac Death

Sudden cardiac death (SCD) is a major public health issue and ranks among the leading causes of mortality in the developed world. The mechanism of death is mostly malignant ventricular arrhythmia. The underlying etiology is primarily ischemic heart disease, although susceptibility to SCD is a complex process with multiple interactions between genes that regulate cardiac and vascular function and other physiological factors. A minority of cases of cardiac arrest or SCD occur in the context of hereditary channelopathies, without overt structural heart disease, such as Brugada syndrome, long QT syndrome, or catecholaminergic polymorphic VT. Prevention of SCD is hampered by our inability to predict who is at risk at an individual level, since the majority of cases occur as the index event without associated high-risk features. In patients with high-risk features for SCD, antiarrhythmic drugs do not reduce mortality and, in fact, can contribute to arrhythmic death, particularly in those with impaired left ventricular systolic function. The ICD is the only proven treatment for prevention of SCD. The advent of the ICD has been perceived as a panacea for SCD, although in reality the degree of residual risk is significant. Ongoing research into genetic susceptibilities and the development of complex computer modeling may provide us with a better understanding of this complex disease process in the future. Until such time, SCD is destined to remain a significant public health threat that requires further study.

[1]  S. Connolly,et al.  Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study. , 2000, European heart journal.

[2]  J F Leclercq,et al.  Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. , 1989, American heart journal.

[3]  A. Skanes,et al.  Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia. , 2011, Heart rhythm.

[4]  S. Hohnloser,et al.  Mechanisms of Sudden Cardiac Death in Myocardial Infarction Survivors: Insights From the Randomized Trials of Implantable Cardioverter-Defibrillators , 2007, Circulation.

[5]  Robert J. Myerburg,et al.  Implantable cardioverter-defibrillators after myocardial infarction. , 2008, The New England journal of medicine.

[6]  S. Priori,et al.  Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. , 2005, JAMA.

[7]  J. Healey,et al.  Derivation and Validation of a Simple Exercise-Based Algorithm for Prediction of Genetic Testing in Relatives of LQTS Probands , 2011, Circulation.

[8]  S. Priori,et al.  Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. , 2000, Circulation.

[9]  Lars Eckardt,et al.  Role of programmed ventricular stimulation in patients with Brugada syndrome: a meta-analysis of worldwide published data. , 2007, European heart journal.

[10]  W. Shimizu,et al.  Body Surface Distribution and Response to Drugs of ST Segment Elevation in Brugada Syndrome: Clinical Implication of Eighty‐Seven–Lead Body Surface Potential Mapping and Its Application to Twelve‐Lead Electrocardiograms , 2000, Journal of cardiovascular electrophysiology.

[11]  D. Zipes,et al.  Use of Nonantiarrhythmic Drugs for Prevention of Sudden Cardiac Death , 2003, Journal of cardiovascular electrophysiology.

[12]  J. Brugada,et al.  Should patients with an asymptomatic Brugada electrocardiogram undergo pharmacological and electrophysiological testing? , 2005, Circulation.

[13]  A. Leenhardt,et al.  Incidence and Risk Factors of Arrhythmic Events in Catecholaminergic Polymorphic Ventricular Tachycardia , 2009, Circulation.

[14]  A. Wilde,et al.  Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. , 2011, Journal of the American College of Cardiology.

[15]  J. Healey,et al.  Systematic Assessment of Patients With Unexplained Cardiac Arrest: Cardiac Arrest Survivors With Preserved Ejection Fraction Registry (CASPER) , 2009, Circulation.

[16]  J. Brugada,et al.  Determinants of Sudden Cardiac Death in Individuals With the Electrocardiographic Pattern of Brugada Syndrome and No Previous Cardiac Arrest , 2003, Circulation.

[17]  K M Kessler,et al.  Frequency of sudden cardiac death and profiles of risk. , 1997, The American journal of cardiology.

[18]  A. Skanes,et al.  Utility of the recovery electrocardiogram after exercise: a novel indicator for the diagnosis and genotyping of long QT syndrome? , 2010, Heart rhythm.

[19]  G. Breithardt,et al.  Implantable cardioverter-defibrillator therapy in patients with congenital long-QT syndrome: a long-term follow-up. , 2005, Heart rhythm.

[20]  S. Priori,et al.  Left Cardiac Sympathetic Denervation in the Management of High-Risk Patients Affected by the Long-QT Syndrome , 2004, Circulation.

[21]  A. Moss,et al.  QT Interval: How to Measure It and What Is “Normal” , 2006, Journal of cardiovascular electrophysiology.

[22]  Bertram Pitt,et al.  Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction , 1996, The Lancet.

[23]  A. Skanes,et al.  Repolarization Dynamics During Exercise Discriminate Between LQT1 and LQT2 Genotypes , 2010, Journal of cardiovascular electrophysiology.

[24]  J J Heger,et al.  Sudden cardiac death. , 1998, Circulation.

[25]  Wataru Shimizu,et al.  Brugada syndrome: report of the second consensus conference. , 2005, Heart rhythm.

[26]  A. Skanes,et al.  How to Perform and Interpret Provocative Testing for the Diagnosis of Brugada Syndrome, Long-QT Syndrome, and Catecholaminergic Polymorphic Ventricular Tachycardia , 2011, Circulation. Arrhythmia and electrophysiology.

[27]  J. Oss,et al.  PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION , 2002 .

[28]  M Borggrefe,et al.  Long-Term Prognosis of Patients Diagnosed With Brugada Syndrome: Results From the FINGER Brugada Syndrome Registry , 2010, Circulation.

[29]  J. Jalife,et al.  Cardiac Electrophysiology: From Cell to Bedside , 1990 .

[30]  George A. Mensah,et al.  Sudden Cardiac Death in the United States, 1989 to 1998 , 2001, Circulation.

[31]  D. Haines,et al.  Transient ST elevation after transthoracic cardioversion in patients with hemodynamically unstable ventricular tachyarrhythmia. , 2000, The American journal of cardiology.

[32]  Julia A. Critchley,et al.  Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980–2000 , 2004 .

[33]  Carlo Napolitano,et al.  Risk stratification in the long-QT syndrome. , 2003, The New England journal of medicine.

[34]  A. Wilde,et al.  The response of the QT interval to the brief tachycardia provoked by standing: a bedside test for diagnosing long QT syndrome. , 2010, Journal of the American College of Cardiology.

[35]  S. Priori,et al.  Should patients with an asymptomatic Brugada electrocardiogram undergo pharmacological and electrophysiological testing? , 2005, Circulation.

[36]  P Ducimetière,et al.  Predicting sudden death in the population: the Paris Prospective Study I. , 1999, Circulation.

[37]  R. Myerburg,et al.  Sudden Cardiac Death: Exploring the Limits of Our Knowledge , 2001, Journal of cardiovascular electrophysiology.

[38]  H. Huikuri,et al.  Family History and the Risk of Sudden Cardiac Death as a Manifestation of an Acute Coronary Event , 2006, Circulation.

[39]  James A. White,et al.  The role of cardiovascular MRI in heart failure and the cardiomyopathies. , 2007, Cardiology clinics.

[40]  G. Cascino,et al.  Identification of a possible pathogenic link between congenital long QT syndrome and epilepsy , 2009, Neurology.

[41]  S. Viskin,et al.  Efficacy of Quinidine in High-Risk Patients With Brugada Syndrome , 2004, Circulation.

[42]  P. Schwartz,et al.  Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia. , 2008, The New England journal of medicine.

[43]  A. Krahn,et al.  Contemporary Reviews in Cardiovascular Medicine Sudden Cardiac Arrest Without Overt Heart Disease , 2011 .

[44]  H L Greene,et al.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. , 1991, The New England journal of medicine.

[45]  D. Roden Drug-induced prolongation of the QT interval. , 2004, The New England journal of medicine.

[46]  P. Spector Diagnosis and management of sudden cardiac death , 2005, Heart.

[47]  M. Ackerman,et al.  Epinephrine QT Stress Testing in the Evaluation of Congenital Long-QT Syndrome: Diagnostic Accuracy of the Paradoxical QT Response , 2005, Circulation.

[48]  James A. White,et al.  Utility of Cardiovascular Magnetic Resonance in Identifying Substrate for Malignant Ventricular Arrhythmias , 2012, Circulation. Cardiovascular imaging.

[49]  Dan M. Roden,et al.  ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines , 2006 .

[50]  Mark Josephson,et al.  Implantable Defibrillators and Sudden Cardiac Death , 2004, Circulation.

[51]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.